Cipla Remains Upbeat On Abraxane As US Generic Competition Looms
Indian Firm Continuing Talks With FDA For Complex ANDA Product
Cipla has provided the latest on its US complex pipeline ahead of several potential launches in the firm’s upcoming 2022/23 financial year. The Indian firm enjoyed 6% group revenue growth in Q3 FY2022 and is on track to hit its EBITDA margin target.
